Hansoh Pharmaceutical Group Co (HKSE:03692) Stock Based Compensation: HK$ Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:03692 Hansoh Pharmaceutical Group Co Ltd HKSE:03692
91 GF Score
Price HK$35.56
GF Value HK$27.12
Valuation Significantly Overvalued
View Full Analysis

What is Hansoh Pharmaceutical Group Co Stock Based Compensation?

Hansoh Pharmaceutical Group Co HKSE:03692 +3.67% 91 Stock Based Compensation is HK$ Mil as of Jun. 2026. GuruFocus rates HKSE:03692 with a GF Score™ of 91/100 and a GF Value™ of HK$27.12 (Significantly Overvalued).

Hansoh Pharmaceutical Group Co's Stock Based Compensation for the six months ended in Jun. 2026 was HK$ Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 was HK$ Mil.

Hansoh Pharmaceutical Group Co Stock Based Compensation Related Terms

Hansoh Pharmaceutical Group Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Hansoh Pharmaceutical Group Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansoh Pharmaceutical Group Co Stock Based Compensation Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 78.91 208.64 189.36 149.32 155.38

Hansoh Pharmaceutical Group Co Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.24 76.17 84.41 72.43 -
HKSE:03692
91GF Score
Hansoh Pharmaceutical Group Co Ltd HKSE:03692
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansoh Pharmaceutical Group Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$ Mil.

What does a Stock Based Compensation of HK$ Mil mean?
Hansoh Pharmaceutical Group Co (HKSE:03692) has a Stock Based Compensation of HK$ Mil as of Jun. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Hansoh Pharmaceutical Group Co and its competitors.
Is Hansoh Pharmaceutical Group Co's Stock Based Compensation too high?
Hansoh Pharmaceutical Group Co's current Stock Based Compensation is HK$ Mil. Overall, Hansoh Pharmaceutical Group Co has a GF Score™ of 91/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansoh Pharmaceutical Group Co's Stock Based Compensation compare to ZTS?
Hansoh Pharmaceutical Group Co's Stock Based Compensation of HK$ Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Hansoh Pharmaceutical Group Co and its competitors. Hansoh Pharmaceutical Group Co's current Stock Based Compensation is HK$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansoh Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co (HKSE:03692) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$27.12, compared to a current price of HK$35.56 — trading 31.1% above its estimated fair value. The current Stock Based Compensation is HK$ Mil. Hansoh Pharmaceutical Group Co's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Hansoh Pharmaceutical Group Co (HKSE:03692), the current Stock Based Compensation is HK$ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansoh Pharmaceutical Group Co (HKSE:03692) Overvalued in 2026?

Based on GuruFocus' analysis, Hansoh Pharmaceutical Group Co stock appears to be overvalued. The current stock price of HK$35.56 is trading 31.1% above its estimated GF Value™ of HK$27.12. GuruFocus considers Hansoh Pharmaceutical Group Co to be Significantly Overvalued.

Key valuation signals for HKSE:03692:

  • Stock Based Compensation: HK$ Mil
  • GF Value™: HK$27.12 vs. price of HK$35.56 (31.1% above fair value)
  • GF Score™: 91/100

No single metric tells the full story. See the HKSE:03692 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansoh Pharmaceutical Group Co Business Description

Address No. 287 Xiangke Road, Pudong New Area, Shanghai, CHN
Hansoh Pharmaceutical Group Co Ltd is an investment holding company. The company were principally engaged in the research and development, production and sale of a series of pharmaceutical products in the People's Republic of China. It focuses on disease therapeutic areas such as oncology, anti-infectives, CNS, metabolism and immunology. The majority of Group's revenue was generated from the sale of pharmaceutical products in Chinese mainland.
91GF Score

Get the complete analysis for HKSE:03692

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$35.56
Price
HK$27.12
GF Value